Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome
Open accessThe DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD) is a chronic complex inflammatory gut pathological condition, examples of which include Crohn’s disease (CD) and ulcerative colitis (UC), which is associated with significant morbidity. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The gut microbiota acts as a metabolic organ and contributes to human health by performing various physiological functions; deviation in the gut flora composition is involved in various disease pathologies, including IBD. This review aims to summarize the current knowledge of gut microbiota alteration in IBD and how this contributes to intestinal inflammation, as well as explore the potential role of gut microbiota-based treatment approaches for the prevention and treatment of IBD. The current literature has clearly demonstrated a perturbation of the gut microbiota in IBD patients and mice colitis models, but a clear causal link of cause and effect has not yet been presented. In addition, gut microbiota-based therapeutic approaches have also shown good evidence of their effects in the amelioration of colitis in animal models (mice) and IBD patients, which indicates that gut flora might be a new promising therapeutic target for the treatment of IBD. However, insufficient data and confusing results from previous studies have led to a failure to define a core microbiome associated with IBD and the hidden mechanism of pathogenesis, which suggests that well-designed randomized control trials and mouse models are required for further research. In addition, a better understanding of this ecosystem will also determine the role of prebiotics and probiotics as therapeutic agents in the management of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in sex hormones levels may lead to microbial dysbiosis which has been previously implicated in IBD and its symptom severity.(40)”
From Association Between Sex Hormone Levels and Gut Microbiota Composition and Diversity—A Systematic Review (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624 · cited 3×
“25% (fewer) of the mucosal microbial genes of healthy individuals [25].”
BackgroundInfluentialChanges of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087 · cited 1×
“The highest incidence rate has been recorded in developed countries, such as North America, Europe, Australia, and New Zealand [6], while recently, IBD has been gradually becoming more common in developing areas such as Asia and South America, and in developing countries such as including Brazil, South Korea, and Chin…”
BackgroundAssociation of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591 · cited 2×
“The NOD2 (nucleotide-binding oligomerization domain containing protein 2), a first gene locus, has been reported as a risk locus for Crohn’s disease (CD) [175,176].”
BackgroundDe Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., Collini, S., Pieraccini, G., & Lionetti, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005963107 · Cited by 5,579 · cited 1×
“Human Bacteroidetes Firmicutes, Enterobacteriaceae Decrease Increase [163]”
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030 · cited 1×
“The NOD2 (nucleotide-binding oligomerization domain containing protein 2), a first gene locus, has been reported as a risk locus for Crohn’s disease (CD) [175,176].”
BackgroundDiarrheagenic Escherichia coli
Nataro, J. P., & Kaper, J. B. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.1.142 · Cited by 5,006 · cited 1×
“Many studies in human IBD patients have reported the commensal bacteria association with the patient’s intestines; for example, an association of adherent/invasive Escherichia coli (AIEC), a normal gut flora of the Enterobacteriaceae group, has been found with CD [121].”
BackgroundMetabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838 · cited 1×
“In addition, certain symbiotic gut microbiota members have been reported to have distinct and specific effects on the host immune system, and are considered key to immune homeostasis [31,37,38].”
BackgroundHost–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · cited 1×
“Genome-wide association studies (GWAS) have identified more than 160 genetic loci associated with conferring protection from IBD or increased risk to IBD development [172].”
BackgroundRichness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Frank, D. N., St. Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706625104 · Cited by 4,611 · cited 8×
“More in-depth studies con ucted in UC nd CD patien s have shown a clear r ductio in Firmicutes (especially Clostridium groups) and an cr ase in Proteobacteria [28,84,85], alongside a significant decre se of many other benefic al bacterial species from the genera Bacteriodes, Lactobacillus, and Eubacterium [86,87].”
BackgroundInfluentialInduction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
Autophagy and Viruses: Adversaries or Allies?
Dong, X., & Levine, B. (2013) · Journal of Innate Immunity · doi:10.1159/000346388 · Cited by 4,430
Gut microbiota in health and disease
Sekirov, I., Russell, S. L., Antunes, L. C. M., & Finlay, B. B. (2010) · Physiological Reviews · doi:10.1152/physrev.00045.2009 · Cited by 4,182
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788
The impact of the gut microbiota on human health: an integrative view
Clemente, J. C., Ursell, L. K., Parfrey, L. W., & Knight, R. (2012) · Cell · doi:10.1016/j.cell.2012.01.035 · Cited by 3,710
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“A randomized control study that compared FMT with antibiotics to treat patients for recurrent Clostridium difficile infection found quite striking differences [257].”
BackgroundAntimicrobial Autophagy: A Conserved Innate Immune Response in Drosophila
Moy, R. H., & Cherry, S. (2013) · Journal of Innate Immunity · doi:10.1159/000350326 · Cited by 3,539
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.005 · Cited by 3,220 · cited 2×
“G vers an coll agues emons rated a correlat on between loss of s ecies diversity and the disease activity index of CD pati nts [83].”
BackgroundAntiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 1×
“Commonly recommended standard therapies for IBD-UC patients are corticosteroids [17], amino-salicylates [18,19], and immunosuppressive agents [20,21].”
BackgroundMulti-omics of the gut microbial ecosystem in inflammatory bowel diseases
Lloyd-Price, J., Arze, C., Ananthakrishnan, A. N., Schirmer, M., Avila-Pacheco, J., Poon, T. W., Andrews, E., Ajami, N. J., Bonham, K. S., Brislawn, C. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1237-9 · Cited by 3,143 · cited 2×
“A recently published study of 132 IBD patients provided the most comprehensive description to date of host and microbial activities in inflammatory bowel diseases, demonstrating that the gut microbiome and the molecular functional profile in terms of transcriptome and metabolome, and the host immune factors, are centr…”
BackgroundThe Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice
Turnbaugh, P. J., Ridaura, V. K., Faith, J. J., Rey, F. E., Knight, R., & Gordon, J. I. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000322 · Cited by 3,058
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039 · cited 1×
“The defects and variations seen in most of these genes can be attributed to microbial recognition and killing functions, mucosa barrier integrity, and immune regulation [70,173,174].”
BackgroundAn Immunomodulatory Molecule of Symbiotic Bacteria Directs Maturation of the Host Immune System
Mazmanian, S. K., Liu, C. H., Tzianabos, A. O., & Kasper, D. L. (2005) · Cell · doi:10.1016/j.cell.2005.05.007 · Cited by 2,910
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V., Reyes, J. A., Shah, S. A., LeLeiko, N., Snapper, S. B., et al. (2012) · Genome Biology · doi:10.1186/gb-2012-13-9-r79 · Cited by 2,713 · cited 1×
“Human Firmicutes: Roseburia, Phascolarctobacterium Enterobacteriaceae: Escherichia/Shigella, Ruminococcus gnavus Decrease [156]”
BackgroundAbraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712
The global burden of IBD: from 2015 to 2025
Kaplan, G. G. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.150 · Cited by 2,639 · cited 1×
“public health challenge [3], and the frequency of incidence is progressively increasing across the globe [4,5].”
BackgroundOkayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y., & Nakaya, R. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90290-h · Cited by 2,401 · cited 1×
“DSS-colitis Bacteroides distasonis, Clostridium ramosum, Akkermansia muciniphila, Enterobacteriaceae Increase [165,166]”
BackgroundNasir, O. (2013) · Kidney and Blood Pressure Research · doi:10.1159/000350152 · Cited by 2,331
Short-chain fatty acids in control of body weight and insulin sensitivity
Canfora, E. E., Jocken, J. W., & Blaak, E. E. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.128 · Cited by 2,298
Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., et al. (2006) · Gut · doi:10.1136/gut.2005.073817 · Cited by 2,277 · cited 4×
“The reduced and altered gut microbiota composition has also been documented in IBD patients’ fecal and mucosa samples [51,89].”
BackgroundInfluentialIntestinal inflammation targets cancer-inducing activity of the microbiota
Arthur, J. C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T.-J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., et al. (2012) · Science · doi:10.1126/science.1224820 · Cited by 2,263
Role of the gut microbiota in immunity and inflammatory disease
Kamada, N., Seo, S.-U., Chen, G. Y., & Núñez, G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3430 · Cited by 2,256
Gutierrez, M. G., Master, S. S., Singh, S. B., Taylor, G. A., Colombo, M. I., & Deretic, V. (2004) · Cell · doi:10.1016/j.cell.2004.11.038 · Cited by 2,252 · cited 1×
“Similarly, the demonstration of MAP persistence in macrophages of mice deficient in the autophagy ATG16L1 gene proved the role of MAP in intestinal inflammation [134,135].”
BackgroundRound, J. L., & Mazmanian, S. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909122107 · Cited by 2,233 · cited 1×
“Some other studies have reported that certain bacterial antigenic signals, such as the retinoic acid of Clostridium cluster IV and XIVa [45], and polysaccharide A of Bacteroides fragilis [46] and Faecalibacterium prausnitzii [47], are involved in triggering an immune response and the accumulation of Treg cells.”
BackgroundThe role of the gut microbiota in nutrition and health
Flint, H. J., Scott, K. P., Louis, P., & Duncan, S. H. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.156 · Cited by 2,182
Reciprocal T H 17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid
Mucida, D., Park, Y., Kim, G., Turovskaya, O., Scott, I., Kronenberg, M., & Cheroutre, H. (2007) · Science · doi:10.1126/science.1145697 · Cited by 1,982 · cited 3×
“Ano her study has shown the association of five bacterial sp cies, including an increase n Rumi ococcus gnavus and a decr ase in Bifidobacte ium adole centis, Dialister invisus, Faecalibacterium prausnitzii, and a unknown member of Clostridium cl ter XIVa [82].”
BackgroundMicrobial Influences in Inflammatory Bowel Diseases
Sartor, R. B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.059 · Cited by 1,927 · cited 4×
“More in-depth studies conducted in UC and CD patients have shown a clear reduction in Firmicutes (especially Clostridium groups) and an increase in Proteobacteria [28,84,85], alongside a significant decrease of many other beneficial bacterial species from the genera Bacteriodes, Lactobacillus, and Eubacterium [86,87].”
BackgroundInfluentialMachiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., Ballet, V., Claes, K., Van Immerseel, F., Verbeke, K., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-304833 · Cited by 1,904 · cited 1×
“Human Roseburia hominis, Faecalibacterium prausnitzii Decrease [161]”
Hampe, J., Franke, A., Rosenstiel, P., Till, A., Teuber, M., Huse, K., Albrecht, M., Mayr, G., De La Vega, F. M., Briggs, J., et al. (2007) · Nature Genetics · doi:10.1038/ng1954 · Cited by 1,897
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789 · cited 2×
“individuals and IBD patients in terms of load and diversity has been confirmed [75,76].”
BackgroundGut microbiota and IBD: causation or correlation?
Ni, J., Wu, G. D., Albenberg, L., & Tomov, V. T. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.88 · Cited by 1,778 · cited 2×
“inhibition of colonic inflammation [48] (Figure 1).”
BackgroundSchwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
The gut microbiome in health and in disease
Shreiner, A. B., Kao, J. Y., & Young, V. B. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000139 · Cited by 1,682
Immunopathogenesis of IBD: current state of the art
de Souza, H. S. P., & Fiocchi, C. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.186 · Cited by 1,551
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548 · cited 1×
“The guidelines are very cautious in defining the exact role of prebiotics in IBD and do not allow the use of prebiotics in either UC or CD [231].”
BackgroundA key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells
Cadwell, K., Liu, J. Y., Brown, S. L., Miyoshi, H., Loh, J., Lennerz, J. K., Kishi, C., Kc, W., Carrero, J. A., Hunt, S., et al. (2008) · Nature · doi:10.1038/nature07416 · Cited by 1,542 · cited 1×
“ATG16L1 deficiency has been found in association with a decrease in Paneth cell function, while polymorphism in the ATG16L1 gene affected the immune pathways which are involved in executing autophagy and in the proper handling of intracellular bacteria [187].”
BackgroundMoayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499 · cited 2×
“Similarly, a randomized trial including approximately 70 UC patients conducted by Moayyedi and colleagues demonstrated that FMT was safe and induced disease remission in more patients compared to placebo [108].”
BackgroundResultPrebiotics: The Concept Revisited1,
Roberfroid, M. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.3.830s · Cited by 1,498
Sellon, R. K., Tonkonogy, S., Schultz, M., Dieleman, L. A., Grenther, W., Balish, E., Rennick, D. M., & Sartor, R. B. (1998) · Infection and Immunity · doi:10.1128/iai.66.11.5224-5231.1998 · Cited by 1,483
Immune adaptations that maintain homeostasis with the intestinal microbiota
Hooper, L. V., & Macpherson, A. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2710 · Cited by 1,454 · cited 2×
“In addition, certain symbiotic gut microbiota members have been reported to have distinct and specific effects on the host immune system, and are considered key to immune homeostasis [31,37,38].”
BackgroundGaboriau-Routhiau, V., Rakotobe, S., Lécuyer, E., Mulder, I., Lan, A., Bridonneau, C., Rochet, V., Pisi, A., De Paepe, M., Brandi, G., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.020 · Cited by 1,452
Interactions between the microbiota and pathogenic bacteria in the gut
Bäumler, A. J., & Sperandio, V. (2016) · Nature · doi:10.1038/nature18849 · Cited by 1,420
Nod2, a Nod1/Apaf-1 Family Member That Is Restricted to Monocytes and Activates NF-κB
Ogura, Y., Inohara, N., Benito, A., Chen, F. F., Yamaoka, S., & Núñez, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008072200 · Cited by 1,361 · cited 1×
“The NOD2 variants might lose this negative repressive role on the Toll-like receptor, leading to dysregulated activation of the NFκB immune signaling pathway, resulting in a high immune response that may be linked to IBD [178].”
BackgroundButyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease
Segain, J.-P., de la Blétière, D. R., Bourreille, A., Leray, V, Gervois, N., Rosales, C., Ferrier, L., Bonnet, C., Blottière, H. M., & Galmiche, J.-P. (2000) · Gut · doi:10.1136/gut.47.3.397 · Cited by 1,321
The fundamental basis of inflammatory bowel disease
Strober, W., Fuss, I., & Mannon, P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30587 · Cited by 1,319
Ott, S. J., Musfeldt, M., Wenderoth, D. F., Hampe, J., Brant, O., Fölsch, U. R., Timmis, K. N., & Schreiber, S. (2004) · Gut · doi:10.1136/gut.2003.025403 · Cited by 1,311 · cited 1×
“Human Firmicutes, Bacteroides species, Eubacterium species, Lactobacillus species Proteobacteria Enterobacteriaceae, Decrease Increase [157]”
BackgroundDynamics of the human gut microbiome in inflammatory bowel disease
Halfvarson, J., Brislawn, C. J., Lamendella, R., Vázquez-Baeza, Y., Walters, W. A., Bramer, L. M., D'Amato, M., Bonfiglio, F., McDonald, D., Gonzalez, A., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.4 · Cited by 1,204 · cited 1×
“Human Prevotella copri, Faecalibacterium prauznitzii Enterobacteriaceae Decrease Increase [159]”
BackgroundKostic, A. D., Gevers, D., Siljander, H., Vatanen, T., Hyötyläinen, T., Hämäläinen, A.-M., Peet, A., Tillmann, V., Pöhö, P., Mattila, I., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.01.001 · Cited by 1,186
Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity
Schirmer, M., Smeekens, S. P., Vlamakis, H., Jaeger, M., Oosting, M., Franzosa, E. A., ter Horst, R., Jansen, T., Jacobs, L., Bonder, M. J., et al. (2016) · Cell · doi:10.1016/j.cell.2016.10.020 · Cited by 1,157 · cited 2×
“An imbalance of the Th17/Treg correlation and t ir pro-inflamma o y cytokines productio is particularly problematic [57,58], as it either causes initiation or p op gation of disease pathogenesis, suggesting a link between dysbiosis and disease etiology [59–67] (Fig r 2).”
BackgroundTaurog, J. D., Richardson, J. A., Croft, J. T., Simmons, W. A., Zhou, M., Fernández-Sueiro, J. L., Balish, E., & Hammer, R. E. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.6.2359 · Cited by 1,156
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial
Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K. M., Brigidi, P., Vitali, B., Poggioli, G., Miglioli, M., & Campieri, M. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00171-9 · Cited by 1,147 · cited 1×
“Prebiotics are indigestible food ingredients, usually carbohydrates, which can promote the growth and activity of selected beneficial gut microbes and provide benefits to the host’s well-being by the amelioration of enteric dysfunction [113].”
BackgroundA Primitive T Cell-Independent Mechanism of Intestinal Mucosal IgA Responses to Commensal Bacteria
Macpherson, A. J., Gatto, D., Sainsbury, E., Harriman, G. R., Hengartner, H., & Zinkernagel, R. M. (2000) · Science · doi:10.1126/science.288.5474.2222 · Cited by 1,113 · cited 4×
“More in-depth studies conducted in UC and CD patients have shown a clear reduction in Firmicutes (especially Clostridium groups) and an increase in Proteobacteria [28,84,85], alongside a significant decrease of many other beneficial bacterial species from the genera Bacteriodes, Lactobacillus, and Eubacterium [86,87].”
BackgroundInfluentialEpithelial NEMO links innate immunity to chronic intestinal inflammation
Nenci, A., Becker, C., Wullaert, A., Gareus, R., van Loo, G., Danese, S., Huth, M., Nikolaev, A., Neufert, C., Madison, B., et al. (2007) · Nature · doi:10.1038/nature05698 · Cited by 1,077 · cited 1×
“Moreover, the deletion of NEMO (NF-kB essential modulator), a luminal mucosal cell-specific gene involved in NF-kB signal transduction, induced TNF-α driven intestinal apoptosis in mice colon epithelial cells [193].”
BackgroundAdams, J. B., Johansen, L. J., Powell, L. D., Quig, D., & Rubin, R. A. (2011) · BMC Gastroenterology · doi:10.1186/1471-230x-11-22 · Cited by 1,076
Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives
Joossens, M., Huys, G., Cnockaert, M., De Preter, V., Verbeke, K., Rutgeerts, P., Vandamme, P., & Vermeire, S. (2011) · Gut · doi:10.1136/gut.2010.223263 · Cited by 1,063 · cited 4×
“Ano her study has shown the association of five bacterial sp cies, including an increase n Rumi ococcus gnavus and a decr ase in Bifidobacte ium adole centis, Dialister invisus, Faecalibacterium prausnitzii, and a unknown member of Clostridium cl ter XIVa [82].”
BackgroundInfluentialWilling, B. P., Dicksved, J., Halfvarson, J., Andersson, A. F., Lucio, M., Zheng, Z., Järnerot, G., Tysk, C., Jansson, J. K., & Engstrand, L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.049 · Cited by 1,032 · cited 3×
“Human Faecalibacterium and Roseburia Enterobacteriaceae and Ruminococcus gnavus Decrease Increase [52]”
BackgroundReduced Paneth cell α-defensins in ileal Crohn's disease
Wehkamp, J., Salzman, N. H., Porter, E., Nuding, S., Weichenthal, M., Petras, R. E., Shen, B., Schaeffeler, E., Schwab, M., Linzmeier, R., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505256102 · Cited by 988 · cited 2×
“In a human study, patients with CD showed lower expression of the Paneth cell defensin proteins HD5 and HD6, and a reduction in antimicrobial activity [180].”
BackgroundRossen, N. G., Fuentes, S., van der Spek, M. J., Tijssen, J. G., Hartman, J. H. A., Duflou, A., Löwenberg, M., van den Brink, G. R., Mathus-Vliegen, E. M. H., de Vos, W. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.045 · Cited by 921 · cited 1×
“For example, a randomized UC trial reported that no significant differences were found in recipient patients who were treated with fecal transplants obtained from healthy donors [262].”
BackgroundCommunicable Ulcerative Colitis Induced by T-bet Deficiency in the Innate Immune System
Garrett, W. S., Lord, G. M., Punit, S., Lugo-Villarino, G., Mazmanian, S. K., Ito, S., Glickman, J. N., & Glimcher, L. H. (2007) · Cell · doi:10.1016/j.cell.2007.08.017 · Cited by 918 · cited 1×
“microbiota transferred to wild-type mice, which induced inflammation [106], as well as the successful resolution of Clostridium deficile infection and colitis remission in UC patients who underwent fecal microbiota transplantation (FMT) with samples obtained from healthy individuals [107,108].”
BackgroundCadwell, K., Patel, K. K., Maloney, N. S., Liu, T.-C., Ng, A. C. Y., Storer, C. E., Head, R. D., Xavier, R., Stappenbeck, T. S., & Virgin, H. W. (2010) · Cell · doi:10.1016/j.cell.2010.05.009 · Cited by 900 · cited 1×
“Further, the concept that a host with genetic susceptibility fails to deal efficiently with invasive bacteria or pathogens due to defects in their pathogen recognition and handling system was supported by a recent study that showed an induction of colitis in ATG16L1 gene-deficient mice, while no colitis occurred in co…”
ResultCaspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis
Günther, C., Martini, E., Wittkopf, N., Amann, K., Weigmann, B., Neumann, H., Waldner, M. J., Hedrick, S. M., Tenzer, S., Neurath, M. F., et al. (2011) · Nature · doi:10.1038/nature10400 · Cited by 884 · cited 2×
“Similarly, mice deficient in the caspase-8- gene, an intestinal epithelial cell-specific gene, experienced spontaneous ileitis [188].”
BackgroundPresence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease
Darfeuille-Michaud, A., Neut, C., Barnich, N., Lederman, E., Di Martino, P., Desreumaux, P., Gambiez, L., Joly, B., Cortot, A., & Colombel, J.-F. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70019-8 · Cited by 877 · cited 1×
“coli (AIEC) compared to healthy controls [123,124].”
Mechanisms of inflammation-driven bacterial dysbiosis in the gut
Zeng, M. Y., Inohara, N., & Nuñez, G. (2017) · Mucosal Immunology · doi:10.1038/mi.2016.75 · Cited by 877 · cited 5×
“This disruption in the gut mic obiota balance ulti ately results in an alteration of t gut micro flora-associated functions, including alteration of fermentation products such as carbohydr tes, vit mi s, and SCFAs [53], and biochemical proces alteratio s, such as immune equilibrium imbalance [54–56].”
BackgroundInfluentialNOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses
Watanabe, T., Kitani, A., Murray, P. J., & Strober, W. (2004) · Nature Immunology · doi:10.1038/ni1092 · Cited by 840 · cited 1×
“It is also speculated that CD-associated NOD2 variants might allow intracellular infiltration of bacteria and allow them to escape from immune cell phagocytosis, resulting in a high immune response [179].”
BackgroundIntestinal Bacterial Colonization Induces Mutualistic Regulatory T Cell Responses
Geuking, M. B., Cahenzli, J., Lawson, M. A. E., Ng, D. C. K., Slack, E., Hapfelmeier, S., McCoy, K. D., & Macpherson, A. J. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.021 · Cited by 840
Rath, H. C., Herfarth, H. H., Ikeda, J. S., Grenther, W. B., Hamm, T. E., Balish, E., Taurog, J. D., Hammer, R. E., Wilson, K. H., & Sartor, R. B. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118878 · Cited by 834
A microbial signature for Crohn's disease
Pascal, V., Pozuelo, M., Borruel, N., Casellas, F., Campos, D., Santiago, A., Martinez, X., Varela, E., Sarrabayrouse, G., Machiels, K., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313235 · Cited by 822 · cited 1×
“Human Faecalibacterium prausnitzii Escherichia coli, Fusobacterium Decrese Increase [150]”
BackgroundArchaea and fungi of the human gut microbiome: correlations with diet and bacterial residents
Hoffmann, C., Dollive, S., Grunberg, S., Chen, J., Li, H., Wu, G. D., Lewis, J. D., & Bushman, F. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066019 · Cited by 808
The gut microbiota and inflammatory bowel disease
Matsuoka, K., & Kanai, T. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-014-0454-4 · Cited by 804 · cited 2×
“subjects, and materials and methods of analysis [97].”
BackgroundMethodKRUIS, W., SCHÜTZ, E., FRIC, P., FIXA, B., JUDMAIER, G., & STOLTE, M. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00225.x · Cited by 775 · cited 1×
“The most commonly evaluated single probiotic strains that have been reported to be effective and as safe as mesalazine for the maintenance of remission in active UC patients are Lactobacillus GG [237,238], Escherichia coli Nissle 1917 [239,240], Bifidobacteria [241], and the yeast strain Saccharomyces boulardii [242].”
BackgroundFurrie, E., Macfarlane, S., Kennedy, A., Cummings, J. H., Walsh, S. V., O’Neil, D. A., & Macfarlane, G. T. (2005) · Gut · doi:10.1136/gut.2004.044834 · Cited by 766 · cited 1×
“longum, inulin, and oligofructose mixture used in a randomized double-blind controlled trial with UC patients demonstrated a reduction in endoscopic inflammation, and TNF-a and IL-1b levels [253].”
MethodEffects of short chain fatty acids on gut morphology and function
Scheppach, W. (1994) · Gut · doi:10.1136/gut.35.1_suppl.s35 · Cited by 756 · cited 1×
“However, butyrate is of great importance as it is involved in colonocyte metabolism [211].”
BackgroundAlterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon
Seksik, P., Rigottier-Gois, L., Gramet, G., Sutren, M., Pochart, P., Marteau, P., Jian, R., & Doré, J. (2003) · Gut · doi:10.1136/gut.52.2.237 · Cited by 753
Dysbiosis in inflammatory bowel disease
Tamboli, C. P., Neut, C., Desreumaux, P., & Colombel, J. F. (2004) · Gut · doi:10.1136/gut.53.1.1 · Cited by 743
Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla
Mahowald, M. A., Rey, F. E., Seedorf, H., Turnbaugh, P. J., Fulton, R. S., Wollam, A., Shah, N., Wang, C., Magrini, V., Wilson, R. K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901529106 · Cited by 740
Walker, A. W., Sanderson, J. D., Churcher, C., Parkes, G. C., Hudspith, B. N., Rayment, N., Brostoff, J., Parkhill, J., Dougan, G., & Petrovska, L. (2011) · BMC Microbiology · doi:10.1186/1471-2180-11-7 · Cited by 726 · cited 2×
“Human Bacteroidetes, Enterobacteriaceae Firmicutes Increase Decrease [71]”
Martin, H. M., Campbell, B. J., Hart, C. A., Mpofu, C., Nayar, M., Singh, R., Englyst, H., Williams, H. F., & Rhodes, J. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.054 · Cited by 716 · cited 1×
“coli and non-jejuni Campylobacter) Increase [147,148]”
The immune system and the gut microbiota: friends or foes?
Cerf-Bensussan, N., & Gaboriau-Routhiau, V. (2010) · Nature Reviews Immunology · doi:10.1038/nri2850 · Cited by 704 · cited 1×
“hepaticus, which is a cause of colitis [190].”
BackgroundNUGENT, S. G., KUMAR, D., RAMPTON, D. S., & EVANS, D. F. (2001) · Gut · doi:10.1136/gut.48.4.571 · Cited by 700 · cited 1×
“Commonly recommended standard therapies for IBD-UC patients are corticosteroids [17], amino-salicylates [18,19], and immunosuppressive agents [20,21].”
BackgroundOtt, S. J., Waetzig, G. H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J. A., Cassidy, L., Tholey, A., Fickenscher, H., Seegert, D., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.010 · Cited by 695 · cited 2×
“recommended a sterile fecal filtrate transfer (FFT) instead of intact microorganisms as an FMT suspension to avoid any risk associated with donor fecal microbiota transplantation [107].”
BackgroundTlaskalová-Hogenová, H., Štěpánková, R., Kozáková, H., Hudcovic, T., Vannucci, L., Tučková, L., Rossmann, P., Hrnčíř, T., Kverka, M., Zákostelská, Z., et al. (2011) · Cellular & Molecular Immunology · doi:10.1038/cmi.2010.67 · Cited by 693
Resta-Lenert, S., & Barrett, K. E. (2003) · Gut · doi:10.1136/gut.52.7.988 · Cited by 642
Rapid and Noninvasive Metabonomic Characterization of Inflammatory Bowel Disease
Marchesi, J. R., Holmes, E., Khan, F., Kochhar, S., Scanlan, P., Shanahan, F., Wilson, I. D., & Wang, Y. (2007) · Journal of Proteome Research · doi:10.1021/pr060470d · Cited by 631
Naser, S. A., Ghobrial, G., Romero, C., & Valentine, J. F. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17058-x · Cited by 626
Lepage, P., Häsler, R., Spehlmann, M. E., Rehman, A., Zvirbliene, A., Begun, A., Ott, S., Kupcinskas, L., Doré, J., Raedler, A., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.011 · Cited by 597 · cited 5×
“Though great progress has been made in understanding the key role of the intestinal microbiota in intestinal inflammation and IBD pathogenesis [38], precisely how bacteria contribute to disease pathogenesis remains incompletely understood [51,116,117].”
BackgroundInfluentialFrank, D. N., Robertson, C. E., Hamm, C. M., Kpadeh, Z., Zhang, T., Chen, H., Zhu, W., Sartor, R. B., Boedeker, E. C., Harpaz, N., et al. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21339 · Cited by 594 · cited 1×
“The same results have been validated in recent human studies, supporting the presence of NOD2 risk alleles in correlation with a shift of microbial ecology composition in IBD patients’ colons [182,183].”
ResultNOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer
Couturier-Maillard, A., Secher, T., Rehman, A., Normand, S., De Arcangelis, A., Haesler, R., Huot, L., Grandjean, T., Bressenot, A., Delanoye-Crespin, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62236 · Cited by 572 · cited 1×
“Furthermore, a very elegant experiment in NOD2-deficient mice clearly demonstrated that genetic ablation of NOD2 is a triggering factor of dysbiosis, which is a critical risk component of colitis and colitis-associated carcinogenesis (CAC) in mice [184].”
BackgroundImpact of Clostridium difficile on Inflammatory Bowel Disease
Issa, M., Vijayapal, A., Graham, M. B., Beaulieu, D. B., Otterson, M. F., Lundeen, S., Skaros, S., Weber, L. R., Komorowski, R. A., Knox, J. F., et al. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.12.028 · Cited by 570
Venturi, Gionchetti, Rizzello, Johansson, Zucconi, Brigidi, Matteuzzi, & Campieri (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00560.x · Cited by 567 · cited 1×
“A few studies published on this topic have also reported that VSL#3 induced an increase in the concentration of Bifidobacterium, Lactobacillus and Streptococcus salivarius in the gut, however, its effect returned to the basal levels 15 days after treatment [243].”
BackgroundNod2 is required for the regulation of commensal microbiota in the intestine
Petnicki-Ocwieja, T., Hrncir, T., Liu, Y.-J., Biswas, A., Hudcovic, T., Tlaskalova-Hogenova, H., & Kobayashi, K. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907722106 · Cited by 564 · cited 1×
“The impact of the NOD2 gene on microbial regulation has been addressed in an NOD2 gene knock-out mouse model that showed a highly persistent overgrowth of the pathogenic bacterial species Helicobacter hepaticus [181].”
BackgroundAn Update on the Epidemiology of Inflammatory Bowel Disease in Asia
Thia, K. T., Loftus, Jr., Sandborn, W. J., & Yang, S.-K. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02158.x · Cited by 548 · cited 2×
“The highest incidence rate has been recorded in developed countries, such as North America, Europe, Australia, and New Zealand [6], while recently, IBD has been gradually becoming more common in developing areas such as Asia and South America, and in developing countries such as including Brazil, South Korea, and Chin…”
BackgroundInfluentialRossi, M., Corradini, C., Amaretti, A., Nicolini, M., Pompei, A., Zanoni, S., & Matteuzzi, D. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.10.6150-6158.2005 · Cited by 541 · cited 1×
“Different from traditional western medicine, CAM is gradually welcomed and accepted by patients because of its mild nature, good curative efficacy, and much lower side effects than western drugs [194].”
BackgroundSood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513
Wang, W., Chen, L., Zhou, R., Wang, X., Song, L., Huang, S., Wang, G., & Xia, B. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01500-13 · Cited by 509
Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.218 · Cited by 489
Säemann, M. D., Böhmig, G. A., Österreicher, C. H., Burtscher, H., Parolini, O., Diakos, C., Stöckl, J., Hörl, W. H., & Zlabinger, G. J. (2000) · The FASEB Journal · doi:10.1096/fj.00-0359fje · Cited by 482 · cited 1×
“Butyrate has also been implicated in the remittance of inflammation by imparting anti-inflammatory actions, inhibition of IL-12, downregulation of TNF-α-related cytokines, and upregulation of IL-10 in human monocytes [212], and also possibly by reduction or inhibition of the nuclear translocation of NF-kB [213–215].”
BackgroundLukovac, S., Belzer, C., Pellis, L., Keijser, B. J., de Vos, W. M., Montijn, R. C., & Roeselers, G. (2014) · mBio · doi:10.1128/mbio.01438-14 · Cited by 474 · cited 1×
“Throughout human history, the role of traditional Chinese herbal medicine (TCMs) as CAM in disease control and cure has been indispensable [199,200].”
BackgroundEfficacy of Lactobacillus GG in maintaining remission of ulcerative colitis
ZOCCO, M. A., DAL VERME, L. Z., CREMONINI, F., PISCAGLIA, A. C., NISTA, E. C., CANDELLI, M., NOVI, M., RIGANTE, D., CAZZATO, I. A., OJETTI, V., et al. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02927.x · Cited by 473 · cited 1×
“The most commonly evaluated single probiotic strains that have been reported to be effective and as safe as mesalazine for the maintenance of remission in active UC patients are Lactobacillus GG [237,238], Escherichia coli Nissle 1917 [239,240], Bifidobacteria [241], and the yeast strain Saccharomyces boulardii [242].”
BackgroundButyrate Inhibits NF-κB Activation in Lamina Propria Macrophages of Patients with Ulcerative Colitis
Lührs, H., Gerke, T., Müller, J. G., Melcher, R., Schauber, J., Boxberger, F., Scheppach, W., & Menzel, T. (2002) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655202317316105 · Cited by 464
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis
Ogata, H., Matsui, T., Nakamura, M., Iida, M., Takazoe, M., Suzuki, Y., & Hibi, T. (2006) · Gut · doi:10.1136/gut.2005.081794 · Cited by 462 · cited 1×
“In addition, biological agents such as infliximab and tacrolimus [22] have been used as part of the regime for UC since 1998 and 2006, respectively [23].”
The role of the gut microbiota in nonalcoholic fatty liver disease
Abu-Shanab, A., & Quigley, E. M. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.172 · Cited by 457
Gupta, P., Andrew, H., Kirschner, B. S., & Guandalini, S. (2000) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200010000-00024 · Cited by 429 · cited 1×
“GBF improved the Disease Activity Index (DAI) by elevating the growth of protective bacteria like Bifidobacterium and Eubacterium [218,219] and the fecal butyrate level [220], and by lowering the serum level of CRP [221] and pro-inflammatory cytokines IL-6 and IL-8, along with the suppression of mast cells in UC patie…”
BackgroundThe Gut Microbiota in Immune-Mediated Inflammatory Diseases
Forbes, J. D., Van Domselaar, G., & Bernstein, C. N. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01081 · Cited by 429 · cited 1×
“Though great progress has been made in understanding the key role of the intestinal microbiota in intestinal inflammation and IBD pathogenesis [38], precisely how bacteria contribute to disease pathogenesis remains incompletely understood [51,116,117].”
BackgroundMicrobial network disturbances in relapsing refractory Crohn’s disease
Swiss IBD Cohort Investigators, Yilmaz, B., Juillerat, P., Øyås, O., Ramon, C., Bravo, F. D., Franc, Y., Fournier, N., Michetti, P., Mueller, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0308-z · Cited by 428 · cited 2×
“is involved in CD and UC disease development [91].”
BackgroundResultthe Wellcome Trust Case Control Consortium, Fisher, S. A., Tremelling, M., Anderson, C. A., Gwilliam, R., Bumpstead, S., Prescott, N. J., Nimmo, E. R., Massey, D., Berzuini, C., et al. (2008) · Nature Genetics · doi:10.1038/ng.145 · Cited by 424 · cited 1×
“The defects and variations seen in most of these genes can be attributed to microbial recognition and killing functions, mucosa barrier integrity, and immune regulation [70,173,174].”
BackgroundThe impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models
Nell, S., Suerbaum, S., & Josenhans, C. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2403 · Cited by 398 · cited 1×
“This question has also been addressed in mouse models infected with enteric pathogens to evaluate the colitogenic potential of an individual specific bacterial species to cause chronic inflammation [118].”
BackgroundMartinez-Medina, M., Aldeguer, X., Lopez-Siles, M., González-Huix, F., López-Oliu, C., Dahbi, G., Blanco, J. E., Blanco, J., Garcia-Gil, J. L., & Darfeuille-Michaud, A. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20860 · Cited by 398 · cited 1×
“coli (AIEC) compared to healthy controls [123,124].”
Kato, K., Mizuno, S., Umesaki, Y., Ishii, Y., Sugitani, M., Imaoka, A., Otsuka, M., Hasunuma, O., Kurihara, R., Iwasaki, A., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02268.x · Cited by 397 · cited 5×
“The most commonly evaluated single probiotic strains that have been reported to be effective and as safe as mesalazine for the maintenance of remission in active UC patients are Lactobacillus GG [237,238], Escherichia coli Nissle 1917 [239,240], Bifidobacteria [241], and the yeast strain Saccharomyces boulardii [242].”
BackgroundInfluentialRooks, M. G., Veiga, P., Wardwell-Scott, L. H., Tickle, T., Segata, N., Michaud, M., Gallini, C. A., Beal, C., van Hylckama-Vlieg, J. E. T., Ballal, S. A., et al. (2014) · The ISME Journal · doi:10.1038/ismej.2014.3 · Cited by 389 · cited 1×
“T-bet−/−1, Rag2−/− mice* Mucispirillum, Desulfovibrio, and Helicobacteraceae Increase [168]”
Santoru, M. L., Piras, C., Murgia, A., Palmas, V., Camboni, T., Liggi, S., Ibba, I., Lai, M. A., Orrù, S., Blois, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10034-5 · Cited by 387 · cited 1×
“Human Bacteroidetes, Bacteroides, Flavobacterium, and Oscillospira Proteobacteria, Verrucomicrobia, Fusobacteria, Escherichia, Faecalibacterium, Streptococcus Decrease [152]”
Screening for Bacillus Isolates in the Broiler Gastrointestinal Tract
Barbosa, T. M., Serra, C. R., La Ragione, R. M., Woodward, M. J., & Henriques, A. O. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.2.968-978.2005 · Cited by 372
Randomized Controlled Trial of the Effect of Bifidobacteria-Fermented Milk on Ulcerative Colitis
Ishikawa, H., Akedo, I., Umesaki, Y., Tanaka, R., Imaoka, A., & Otani, T. (2003) · Journal of the American College of Nutrition · doi:10.1080/07315724.2003.10719276 · Cited by 370 · cited 1×
“longum and psyllium, both used in a randomized control trial as a supplement to conventional therapy in UC patients, showed a good synergistic effect and improved the disease clinical activity index compared to a probiotic or prebiotic alone [251,252].”
ResultMycobacterium paratuberculosis DNA in Crohn's disease tissue.
Sanderson, J. D., Moss, M. T., Tizard, M. L., & Hermon-Taylor, J. (1992) · Gut · doi:10.1136/gut.33.7.890 · Cited by 369 · cited 1×
“For example, two different studies have reported a higher level of MAP-DNA in healthy volunteers than in IBD-diseased cases [130,136].”
ResultHold, G. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i5.1192 · Cited by 365 · cited 1×
“Moreover, these strains caused colitis in adult Rag2−/− and wild-type mice [120].”
BackgroundNOD2 and Toll-Like Receptors Are Nonredundant Recognition Systems of Mycobacterium tuberculosis
Ferwerda, G., Girardin, S. E., Kullberg, B.-J., Le Bourhis, L., de Jong, D. J., Langenberg, D. M. L., van Crevel, R., Adema, G. J., Ottenhoff, T. H. M., Van der Meer, J. W. M., et al. (2005) · PLoS Pathogens · doi:10.1371/journal.ppat.0010034 · Cited by 365
Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition
Tanabe, T., Chamaillard, M., Ogura, Y., Zhu, L., Qiu, S., Masumoto, J., Ghosh, P., Moran, A., Predergast, M. M., Tromp, G., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600175 · Cited by 362 · cited 1×
“For example, normally it is suggested that NOD2 acts as a negative regulator of the Toll-like receptor and prevents excessive activation and stimulation of the NFκB immune signaling pathway [177].”
BackgroundSelby, W., Pavli, P., Crotty, B., Florin, T., Radford-Smith, G., Gibson, P., Mitchell, B., Connell, W., Read, R., Merrett, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.031 · Cited by 362 · cited 1×
“However, the more important controversy against MAP causality in IBD pathogenesis is the fact that no efficient antibiotic treatment effects have been shown in IBD patients [137].”
BackgroundKleessen, B., Hartmann, L., & Blaut, M. (2001) · British Journal of Nutrition · doi:10.1079/bjn2001403 · Cited by 341 · cited 1×
“Inulin supplementation has also produced an increased level of butyrate [227,228], alteration of microflora [229], and a decrease in endoscopic histopathology [230].”
BackgroundInflammatory Bowel Disease as a Model for Translating the Microbiome
Huttenhower, C., Kostic, A. D., & Xavier, R. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.013 · Cited by 332 · cited 1×
“The defects and variations seen in most of these genes can be attributed to microbial recognition and killing functions, mucosa barrier integrity, and immune regulation [70,173,174].”
BackgroundAngelberger, S., Reinisch, W., Makristathis, A., Lichtenberger, C., Dejaco, C., Papay, P., Novacek, G., Trauner, M., Loy, A., & Berry, D. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.257 · Cited by 330 · cited 2×
“One patient from study [263], who experienced clinical betterment, showed a very similar gut microbiota composition to the microbiota of the healthy donor for a longer period of time, suggesting that successful transplantation and colonization of microbiota in the recipient patient correlated with the clinical improve…”
BackgroundResultBacteria-triggered CD4+ T Regulatory Cells Suppress Helicobacter hepaticus–induced Colitis
Kullberg, M. C., Jankovic, D., Gorelick, P. L., Caspar, P., Letterio, J. J., Cheever, A. W., & Sher, A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020556 · Cited by 322
DNA from probiotic bacteria modulates murine and human epithelial and immune function
Jijon, H., Backer, J., Diaz, H., Yeung, H., Thiel, D., McKaigney, C., De Simone, C., & Madsen, K. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.003 · Cited by 321
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies
Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2219 · Cited by 320
Nod2 is essential for temporal development of intestinal microbial communities
Rehman, A., Sina, C., Gavrilova, O., Häsler, R., Ott, S., Baines, J. F., Schreiber, S., & Rosenstiel, P. (2011) · Gut · doi:10.1136/gut.2010.216259 · Cited by 316 · cited 1×
“claimed that NOD2 is required for temporal development and composition of the host’s intestinal microbiota [185].”
BackgroundRole of the microbiota in inflammatory bowel diseases
Nagalingam, N. A., & Lynch, S. V. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21866 · Cited by 315 · cited 2×
“individuals and IBD patients in terms of load and diversity has been confirmed [75,76].”
BackgroundDennis, K. L., Wang, Y., Blatner, N. R., Wang, S., Saadalla, A., Trudeau, E., Roers, A., Weaver, C. T., Lee, J. J., Gilbert, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1511 · Cited by 315 · cited 1×
“Colitis inApc468/IL-10−/−mice* Bacteroides and Porphyromonas genera Increased [171]”
BackgroundKunde, S., Pham, A., Bonczyk, S., Crumb, T., Duba, M., Conrad, H., Cloney, D., & Kugathasan, S. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318292fa0d · Cited by 314 · cited 1×
“A phase 1 trial study conducted on pediatric UC patients reported that FMT was quite safe, with a high rate of clinical response (79%) within one week, and no serious side effects were observed [261].”
BackgroundSystematic review: faecal microbiota transplantation in the management of inflammatory bowel disease
Anderson, J. L., Edney, R. J., & Whelan, K. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05220.x · Cited by 313 · cited 1×
“difficile infection, 13 UC patients achieved no colitis disease when treated with FMT [260].”
BackgroundSchultsz, C., van den Berg, F. M., ten Kate, F. W., Tytgat, G. N. J., & Dankert, J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70393-8 · Cited by 312 · cited 2×
“, IBD patient gut flora studies hav always presented an alteration featuring high load and less diversity [88,89].”
BackgroundDecreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease
Fujimoto, T., Imaeda, H., Takahashi, K., Kasumi, E., Bamba, S., Fujiyama, Y., & Andoh, A. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12073 · Cited by 304
Treatment of ulcerative colitis by implantation of normal colonic flora
Bennet, J., & Brinkman, M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91183-5 · Cited by 304 · cited 1×
“The first effort of FMT to treat UC was made in 1989 [258].”
BackgroundIntestinal microbiota in inflammatory bowel disease: Friend of foe?
Fava, F. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i5.557 · Cited by 300 · cited 1×
“Human Clostridium clusters (IV and IXV) Decrease [142]”
BackgroundCui, B., Feng, Q., Wang, H., Wang, M., Peng, Z., Li, P., Huang, G., Liu, Z., Wu, P., Fan, Z., et al. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12727 · Cited by 298 · cited 1×
“The largest study conducted on this topic, which covered a wide range of CD patients, was published recently, and reported that FMT is one of the safest, most efficient, and most effective treatments for refractory CD [259].”
BackgroundRhee, K.-J., Wu, S., Wu, X., Huso, D. L., Karim, B., Franco, A. A., Rabizadeh, S., Golub, J. E., Mathews, L. E., Shin, J., et al. (2009) · Infection and Immunity · doi:10.1128/iai.00814-08 · Cited by 297 · cited 1×
“For example, Bacteroides fragilis, a human commensal bacterial species, causes chronic intestinal inflammation in mice [119].”
BackgroundSCFAs Induce Mouse Neutrophil Chemotaxis through the GPR43 Receptor
Vinolo, M. A. R., Ferguson, G. J., Kulkarni, S., Damoulakis, G., Anderson, K., Bohlooly-Y, M., Stephens, L., Hawkins, P. T., & Curi, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021205 · Cited by 292
Casén, C., Vebø, H. C., Sekelja, M., Hegge, F. T., Karlsson, M. K., Ciemniejewska, E., Dzankovic, S., Frøyland, C., Nestestog, R., Engstrand, L., et al. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13236 · Cited by 289
Current and emerging drugs for the treatment of inflammatory bowel disease
Triantafillidis, J. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s11290 · Cited by 289 · cited 1×
“This current treatment is short term and relieves symptomatic complications, but is accompanied by serious side effects, including loss of immune tolerance and drug resistance [24].”
BackgroundQiu, X., Zhang, M., Yang, X., Hong, N., & Yu, C. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.04.002 · Cited by 286
Roller, M., Rechkemmer, G., & Watzl, B. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.1.153 · Cited by 280 · cited 1×
“, used a mixture of oligofructose-enriched inulin, Lactobacillus, and Bifidobacterium, and reported the suppression of colonic carcinogenesis and improvement of IgA and IL-10 secretion in the colon [250].”
MethodOliva, S., Di Nardo, G., Ferrari, F., Mallardo, S., Rossi, P., Patrizi, G., Cucchiara, S., & Stronati, L. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04939.x · Cited by 280 · cited 1×
“The most commonly evaluated single probiotic strains that have been reported to be effective and as safe as mesalazine for the maintenance of remission in active UC patients are Lactobacillus GG [237,238], Escherichia coli Nissle 1917 [239,240], Bifidobacteria [241], and the yeast strain Saccharomyces boulardii [242].”
BackgroundAdherent and Invasive Escherichia coli Is Associated with Granulomatous Colitis in Boxer Dogs
Simpson, K. W., Dogan, B., Rishniw, M., Goldstein, R. E., Klaessig, S., McDonough, P. L., German, A. J., Yates, R. M., Russell, D. G., Johnson, S. E., et al. (2006) · Infection and Immunity · doi:10.1128/iai.00067-06 · Cited by 278 · cited 1×
“It has also been reported to be a causative agent in granulomatous colitis of boxer dogs [122].”
BackgroundHighlighting new phylogenetic specificities of Crohnʼs disease microbiota
Mondot, S., Kang, S., Furet, J. P., Aguirre de Carcer, D., McSweeney, C., Morrison, M., Marteau, P., Doré, J., & Leclerc, M. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21436 · Cited by 264
Håkansson, Å., Tormo-Badia, N., Baridi, A., Xu, J., Molin, G., Hagslätt, M.-L., Karlsson, C., Jeppsson, B., Cilio, C. M., & Ahrné, S. (2015) · Clinical and Experimental Medicine · doi:10.1007/s10238-013-0270-5 · Cited by 262 · cited 1×
“DSS-colitis Bacteroides distasonis, Clostridium ramosum, Akkermansia muciniphila, Enterobacteriaceae Increase [165,166]”
BackgroundThe Sus operon: a model system for starch uptake by the human gut Bacteroidetes
Foley, M. H., Cockburn, D. W., & Koropatkin, N. M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2242-x · Cited by 262 · cited 1×
“Although the polysaccharides of Chinese HMs are indigestible, and have been less reported in the restoration of the intestinal flora in IBD patients, their pharmacological effects such as immunosuppressive advantage and coexistence with gut microbes have made them excellent prebiotics in IBD adjuvant therapy [203].”
BackgroundNagao-Kitamoto, H., Shreiner, A. B., Gillilland, M. G., Kitamoto, S., Ishii, C., Hirayama, A., Kuffa, P., El-Zaatari, M., Grasberger, H., Seekatz, A. M., et al. (2016) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.02.003 · Cited by 248 · cited 1×
“Gonobiotic mice change in species diversity Species diversity decrease [169]”
BackgroundFecal microbiota transplantation as novel therapy in gastroenterology: A systematic review
Rossen, N. G. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i17.5359 · Cited by 242 · cited 1×
“A systematic meta-analysis study published recently concluded that the reported results of FMT as a treatment approach in IBD are not consistent, and sometimes are quite difficult to interpret [265].”
BackgroundBien, J., Palagani, V., & Bozko, P. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12454590 · Cited by 238
Li, E., Hamm, C. M., Gulati, A. S., Sartor, R. B., Chen, H., Wu, X., Zhang, T., Rohlf, F. J., Zhu, W., Gu, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0026284 · Cited by 236 · cited 1×
“The same results have been validated in recent human studies, supporting the presence of NOD2 risk alleles in correlation with a shift of microbial ecology composition in IBD patients’ colons [182,183].”
ResultKump, P. K., Gröchenig, H.-P., Lackner, S., Trajanoski, S., Reicht, G., Hoffmann, K. M., Deutschmann, A., Wenzl, H. H., Petritsch, W., Krejs, G. J., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31829ea325 · Cited by 235 · cited 1×
“Moreover, two recently published prospective studies in which FMT was used for adult UC patients failed to achieve clinical remission after FMT, though in most of the patients’, significant structural changes were observed in the gut microbiota [263,264].”
ResultJacobs, J. P., Goudarzi, M., Singh, N., Tong, M., McHardy, I. H., Ruegger, P., Asadourian, M., Moon, B.-H., Ayson, A., Borneman, J., et al. (2016) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.06.004 · Cited by 228
Bibiloni, R., Mangold, M., Madsen, K. L., Fedorak, R. N., & Tannock, G. W. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46498-0 · Cited by 226 · cited 1×
“Importantly, the load of bacteria has been shown to be significantly higher in gut affected areas, in the colon and ileum, but lower in the other parts of the GIT, supporting the association of the gut microbiota with gut inflammatory lesions [28,98].”
BackgroundA tale of two diseases: The history of inflammatory bowel disease
Mulder, D. J., Noble, A. J., Justinich, C. J., & Duffin, J. M. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.09.009 · Cited by 225 · cited 2×
“Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract (GI), which is characterized by a disrupted mucosa structure, altered gut microbial composition, and systemic biochemical abnormalities [1].”
BackgroundRole of the enteric microbiota in intestinal homeostasis and inflammation
Koboziev, I., Reinoso Webb, C., Furr, K. L., & Grisham, M. B. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.11.008 · Cited by 223 · cited 2×
“In addition, certain symbiotic gut microbiota members have been reported to have distinct and specific effects on the host immune system, and are considered key to immune homeostasis [31,37,38].”
BackgroundFecal β-D-Galactosidase Production and Bifidobacteria Are Decreased in Crohn's Disease
Favier, C., Neut, C., Mizon, C., Cortot, A., Colombel, J. F., & Mizon, J. (1997) · Digestive Diseases and Sciences · doi:10.1023/a:1018876400528 · Cited by 220
Hoentjen, F., Welling, G. W., Harmsen, H. J. M., Zhang, X., Snart, J., Tannock, G. W., Lien, K., Churchill, T. A., Lupicki, M., & Dieleman, L. A. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000183421.02316.d5 · Cited by 218 · cited 1×
“Inulin supplementation has also produced an increased level of butyrate [227,228], alteration of microflora [229], and a decrease in endoscopic histopathology [230].”
BackgroundAnalysis of bacterial bowel communities of IBD patients: What has it revealed?
Sokol, H., Lay, C., Seksik, P., & Tannock, G. W. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20392 · Cited by 216 · cited 1×
“Human Firmicutes, Faecalibacterium prausnitzii, Bifidobacteria Decrease [151]”
Brown, E. M., Wlodarska, M., Willing, B. P., Vonaesch, P., Han, J., Reynolds, L. A., Arrieta, M.-C., Uhrig, M., Scholz, R., Partida, O., et al. (2015) · Nature Communications · doi:10.1038/ncomms8806 · Cited by 213
Dietary Inulin Improves Distal Colitis Induced by Dextran Sodium Sulfate in the Rat
Videla, S., Vilaseca, J., Antolín, M., García-Lafuente, A., Guarner, F., Crespo, E., Casalots, J., Salas, A., & Malagelada, J. R. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03802.x · Cited by 209 · cited 1×
“Inulin supplementation has also produced an increased level of butyrate [227,228], alteration of microflora [229], and a decrease in endoscopic histopathology [230].”
BackgroundGut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility
Scaldaferri, F., Gerardi, V., Lopetuso, L. R., Del Zompo, F., Mangiola, F., Boškoski, I., Bruno, G., Petito, V., Laterza, L., Cammarota, G., et al. (2013) · BioMed Research International · doi:10.1155/2013/435268 · Cited by 207
Treatment of distal ulcerative colitis with short-chain fatty acid enemas a placebo-controlled trial
Scheppach, W., & German-Austrian Scfa Study Group (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02071409 · Cited by 207
Torow, N., & Hornef, M. W. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601253 · Cited by 207
Wright, E. K., Kamm, M. A., Teo, S. M., Inouye, M., Wagner, J., & Kirkwood, C. D. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000382 · Cited by 202
Fiber, Inulin and Oligofructose: Similarities and Differences
Schneeman, B. O. (1999) · The Journal of Nutrition · doi:10.1093/jn/129.7.1424s · Cited by 200
Ishikawa, H., Matsumoto, S., Ohashi, Y., Imaoka, A., Setoyama, H., Umesaki, Y., Tanaka, R., & Otani, T. (2011) · Digestion · doi:10.1159/000322977 · Cited by 197 · cited 1×
“breve Yakult strain and galactooligosaccharides mixture showed a significant anti-inflammatory effect in mild-to-moderate UC patients [254].”
BackgroundCherbut, C., Michel, C., & Lecannu, G. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.1.21 · Cited by 195 · cited 1×
“Similarly, other studies have investigated the efficacy of fructooligosaccharides (FOS) and have shown a significant increase in the butyrate level [218], and an increase of beneficial bacteria in CD patients and a TNBS-induced colitis model of rats [224,225].”
BackgroundDysbiosis in intestinal inflammation: Cause or consequence
Buttó, L. F., & Haller, D. (2016) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2016.02.010 · Cited by 188 · cited 2×
“associated with a variety of gut pathologies [49] and intestinal inflammation [50].”
BackgroundSheil, B., McCarthy, J., O’Mahony, L., Bennett, M. W., Ryan, P., Fitzgibbon, J. J., Kiely, B., Collins, J. K., & Shanahan, F. (2004) · Gut · doi:10.1136/gut.2003.027789 · Cited by 186
Ward, J. M., Anver, M. R., Haines, D. C., Melhorn, J. M., Gorelick, P. L., Yan, L., & Fox, J. G. (1996) · PubMed · Cited by 186
Govers, M. J. A. P., Gannon, N. J., Dunshea, F. R., Gibson, P. R., & Muir, J. G. (1999) · Gut · doi:10.1136/gut.45.6.840 · Cited by 183 · cited 1×
“coli, while reducing Bacteroidaceae and other potentially pathogenic bacteria [115,209].”
BackgroundBiostructure of Fecal Microbiota in Healthy Subjects and Patients With Chronic Idiopathic Diarrhea
Swidsinski, A., Loening–Baucke, V., Verstraelen, H., Osowska, S., & Doerffel, Y. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.017 · Cited by 178
Tong, M., Li, X., Wegener Parfrey, L., Roth, B., Ippoliti, A., Wei, B., Borneman, J., McGovern, D. P. B., Frank, D. N., Li, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080702 · Cited by 177 · cited 1×
“prausnitzii Bacteroidetes, Proteobacteria Decrease Increase [71,164]”
Reduced Diversity and Imbalance of Fecal Microbiota in Patients with Ulcerative Colitis
Nemoto, H., Kataoka, K., Ishikawa, H., Ikata, K., Arimochi, H., Iwasaki, T., Ohnishi, Y., Kuwahara, T., & Yasutomo, K. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2236-y · Cited by 175 · cited 3×
“More in-depth studies conducted in UC and CD patients have shown a clear reduction in Firmicutes (especially Clostridium groups) and an increase in Proteobacteria [28,84,85], alongside a significant decrease of many other beneficial bacterial species from the genera Bacteriodes, Lactobacillus, and Eubacterium [86,87].”
BackgroundFunctional Impacts of the Intestinal Microbiome in the Pathogenesis of Inflammatory Bowel Disease
Li, J. S. Y., Butcher, J., Mack, D. R., & Stintzi, A. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000215 · Cited by 174
Probiotics and prebiotics in inflammatory bowel disease: microflora ‘on the scope’
Damaskos, D., & Kolios, G. C. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03096.x · Cited by 171 · cited 4×
“coli, while reducing Bacteroidaceae and other potentially pathogenic bacteria [115,209].”
BackgroundInfluentialMycobacterium paratuberculosisis recognized by Toll-like receptors and NOD2
Ferwerda, G., Kullberg, B. J., de Jong, D. J., Girardin, S. E., Langenberg, D. M. L., van Crevel, R., Ottenhoff, T. H. M., van der Meer, J. W. M., & Netea, M. G. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0307147 · Cited by 170 · cited 1×
“has been demonstrated in NOD2 variant CD patients, linking MAP to genetic alteration [132,133].”
BackgroundD’Argenio, V., Casaburi, G., Precone, V., Pagliuca, C., Colicchio, R., Sarnataro, D., Discepolo, V., Kim, S. M., Russo, I., Blanco, G. D. V., et al. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.95 · Cited by 168
Luo, A., Leach, S. T., Barres, R., Hesson, L. B., Grimm, M. C., & Simar, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00417 · Cited by 165 · cited 2×
“An imbalance of the Th17/Treg correlation and t ir pro-inflamma o y cytokines productio is particularly problematic [57,58], as it either causes initiation or p op gation of disease pathogenesis, suggesting a link between dysbiosis and disease etiology [59–67] (Fig r 2).”
BackgroundSha, S., Xu, B., Wang, X., Zhang, Y., Wang, H., Kong, X., Zhu, H., & Wu, K. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.11.022 · Cited by 165 · cited 3×
“More in-depth studies conducted in UC and CD patients have shown a clear reduction in Firmicutes (especially Clostridium groups) and an increase in Proteobacteria [28,84,85], alongside a significant decrease of many other beneficial bacterial species from the genera Bacteriodes, Lactobacillus, and Eubacterium [86,87].”
BackgroundThe gut microbiota in mouse models of inflammatory bowel disease
Gkouskou, K. K., Deligianni, C., Tsatsanis, C., & Eliopoulos, A. G. (2014) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2014.00028 · Cited by 162 · cited 3×
“Gut microbiota alteration in IBD pathology is generally accepted; however, it is unclear whether such an alteration is the cause of intestinal inflammation or a consequence of it, and precisely how these bacteria contribute to IBD pathogenesis remains unclear [13,14].”
BackgroundInfluentialVictoria, C. R., Sassak, L. Y., & Nunes, H. R. D. C. (2009) · Arquivos de Gastroenterologia · doi:10.1590/s0004-28032009000100009 · Cited by 156 · cited 2×
“The highest incidence rate has been recorded in developed countries, such as North America, Europe, Australia, and New Zealand [6], while recently, IBD has been gradually becoming more common in developing areas such as Asia and South America, and in developing countries such as including Brazil, South Korea, and Chin…”
BackgroundInfluentialMardini, H. E., & Grigorian, A. Y. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000084 · Cited by 155 · cited 1×
“A meta-analysis study published recently reported that the VSL#3 cocktail, given in combination with IBD/UC standard therapy, showed significantly higher curative effects in clinical remission compared to standard therapy alone in UC patients [246].”
MethodOhata, A., Usami, M., & Miyoshi, M. (2005) · Nutrition · doi:10.1016/j.nut.2004.12.004 · Cited by 155
Hedin, C. R. H., McCarthy, N. E., Louis, P., Farquharson, F. M., McCartney, S. A., Taylor, K. M., Prescott, N. J., Murrells, T., Stagg, A. J., Whelan, K., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-306226 · Cited by 153
Veltkamp, C., Tonkonogy, S. L., de Jong, Y. P., Albright, C. A., Grenther, W. B., Balish, E., Terhorst, C., & Sartor, R. B. (2001) · Gastroenterology · doi:10.1053/gast.2001.22547 · Cited by 149
The role of infection in the aetiology of inflammatory bowel disease
Hansen, R., Thomson, J., El-Omar, E. M., & Hold, G. L. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-009-0191-y · Cited by 143 · cited 1×
“Similarly, the demonstration of MAP persistence in macrophages of mice deficient in the autophagy ATG16L1 gene proved the role of MAP in intestinal inflammation [134,135].”
BackgroundInvolvement of Bacteria Other Than Clostridium difficile in Antibiotic-Associated Diarrhoea
Larcombe, S., Hutton, M. L., & Lyras, D. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.02.001 · Cited by 143
Intestinal Bacteria Composition and Translocation of Bacteria in Inflammatory Bowel Disease
Vrakas, S., Mountzouris, K. C., Michalopoulos, G., Karamanolis, G. P., Papatheodoridis, G., Tzathas, C., & Gazouli, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170034 · Cited by 143
Kanauchi, O., Mitsuyama, K., Homma, T., Takahama, K., Fujiyama, Y., Andoh, A., Araki, Y., Toshihiro, S., Hibi∥, T., Naganuma, M., et al. (2003) · International Journal of Molecular Medicine · doi:10.3892/ijmm.12.5.701 · Cited by 137 · cited 5×
“Similarly, other studies have investigated the efficacy of fructooligosaccharides (FOS) and have shown a significant increase in the butyrate level [218], and an increase of beneficial bacteria in CD patients and a TNBS-induced colitis model of rats [224,225].”
BackgroundInfluential
Research works printed but not linked: 2
- Zhang, 2007, Wumei pill decoction in the treatment of 72 cases of chronic nonspecific ulcerative colitis, Mod. J. Integr. Tradit. West. Med., 16, 5156
- Yan, 2013, Effect of Astragalus Polysaccharides on Th17/Treg Cytokines and Pulmonary Inflammation in Asthmatic Rats, Chin. Pharmacol. Bull., 29, 1275
Cited by
Postbiotics—A Step Beyond Pre- and Probiotics
Żółkiewicz, J., Marzec, A., Ruszczyński, M., & Feleszko, W. (2020) · Nutrients · doi:10.3390/nu12082189 · Cited by 784
Inflammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues
Lee, M., & Chang, E. B. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.056 · Cited by 645
Gut microbiota and Covid-19- possible link and implications
Dhar, D., & Mohanty, A. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198018 · Cited by 608
Kumar Singh, A., Cabral, C., Kumar, R., Ganguly, R., Kumar Rana, H., Gupta, A., Rosaria Lauro, M., Carbone, C., Reis, F., & Pandey, A. K. (2019) · Nutrients · doi:10.3390/nu11092216 · Cited by 433
Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation
Akhtar, M., Chen, Y., Ma, Z., Zhang, X., Shi, D., Khan, J. A., & Liu, H. (2022) · Animal Nutrition · doi:10.1016/j.aninu.2021.11.005 · Cited by 363
Metadata
- Authors
- Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C.
- Affiliations
- Lanzhou University (CN)
- Gansu Key Laboratory of Functional Genomics and Molecular Diagnosis, Lanzhou 730000, China
- Corresponding author
- Zhang, Chunjiang
- Venue
- Pathogens
- Publisher
- MDPI AG
- Published
- 2019-08-13
- Volume
- 8
- Issue
- 3
- Pages
- 126
- ISSN
- 2076-0817 (ISSN-L)
- PMC
- PMC6789542
- OpenAlex
- W2966933380
- Cited by
- 771
- References
- 267
- Citations by year
- 2026: 43 · 2025: 105 · 2024: 149 · 2023: 134 · 2022: 135 · 2021: 132 · 2020: 66 · 2019: 7
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lanzhou University Institutional Repository (submittedVersion, cc-by-nc-sa)
- Lanzhou University Institutional Repository (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Jiangsu Science and Technology Major Project ((No. BA2016036))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- inflammatory bowel disease, gut microbiota, dysbiosis, Crohn's disease, ulcerative colitis, intestinal inflammation, microbiota-based therapy, probiotics, prebiotics, mouse colitis model, IBD pathogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.